New biomaterials derived from poly(lactic acids) : novel approaches to combine biodegradation, x-ray contrast and controlled local drug release
暂无分享,去创建一个
[1] L. Koole,et al. Synergetic effect observed during development of drug-eluting biodegradable microspheres for transarterial chemoembolization (TACE) of solid tumors. , 2015, Journal of controlled release : official journal of the Controlled Release Society.
[2] Shanyong Zhang,et al. Synergistic growth inhibition by sorafenib and cisplatin in human osteosarcoma cells. , 2015, Oncology reports.
[3] P. Serruys,et al. Early (before 6 months), late (6-12 months) and very late (after 12 months) angiographic scaffold restenosis in the ABSORB Cohort B trial. , 2015, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[4] L. Koole,et al. Preparation and structure of drug-carrying biodegradable microspheres designed for transarterial chemoembolization therapy , 2015, Journal of biomaterials science. Polymer edition.
[5] P. Serruys,et al. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial , 2015, The Lancet.
[6] C. Hamm,et al. Current status of bioresorbable scaffolds in the treatment of coronary artery disease. , 2014, Journal of the American College of Cardiology.
[7] P. Tchounwou,et al. Cisplatin in cancer therapy: molecular mechanisms of action. , 2014, European journal of pharmacology.
[8] P. Serruys,et al. Cost-Effectiveness of Percutaneous Coronary Intervention With Drug-Eluting Stents Versus Bypass Surgery for Patients With 3-Vessel or Left Main Coronary Artery Disease: Final Results From the Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) Trial , 2014, Circulation.
[9] C. Ohmann,et al. TACE plus sorafenib for the treatment of hepatocellular carcinoma: results of the multicenter, phase II SOCRATES trial , 2014, Cancer Chemotherapy and Pharmacology.
[10] P. Bie,et al. Transarterial Chemoembolization (TACE) plus Sorafenib Versus TACE for Intermediate or Advanced Stage Hepatocellular Carcinoma: A Meta-Analysis , 2014, PloS one.
[11] D. Steinberg,et al. Advances in stent technologies and their effect on clinical efficacy and safety , 2014, Medical devices.
[12] Yoshinobu Onuma,et al. Bioresorbable scaffolds: rationale, current status, challenges, and future. , 2014, European heart journal.
[13] R. Whitbourn,et al. Dynamics of vessel wall changes following the implantation of the absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months. , 2014, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[14] R. Waksman,et al. Bioresorbable metal scaffold for cardiovascular application: current knowledge and future perspectives. , 2014, Cardiovascular revascularization medicine : including molecular interventions.
[15] L. Koole,et al. A Nontoxic Additive to Introduce X‐Ray Contrast into Poly(Lactic Acid). Implications for Transient Medical Implants Such as Bioresorbable Coronary Vascular Scaffolds , 2014, Advanced healthcare materials.
[16] T. Harita,et al. Decade of histological follow-up for a fully biodegradable poly-L-lactic acid coronary stent (Igaki-Tamai stent) in humans: are bioresorbable scaffolds the answer? , 2014, Circulation.
[17] N. Chavez-Tapia,et al. Clinical practice guidelines: Management of Hepatocellular Carcinoma , 2014 .
[18] M. Price. Coronary stenting : a companion to Topol's Textbook of interventional cardiology , 2014 .
[19] Yoshinobu Onuma,et al. Bioresorbable Drug-Eluting Magnesium-Alloy Scaffold for Treatment of Coronary Artery Disease , 2013, International journal of molecular sciences.
[20] Y. Shin,et al. Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses. , 2013, Radiology.
[21] D. Quail,et al. Microenvironmental regulation of tumor progression and metastasis , 2014 .
[22] M. Welker,et al. Antiangiogenic treatment in hepatocellular carcinoma: the balance of efficacy and safety , 2013, Cancer management and research.
[23] A. Colombo,et al. Looking into the future with bioresorbable vascular scaffolds , 2013, Expert review of cardiovascular therapy.
[24] O. Abdel-Rahman,et al. Combination Trans Arterial Chemoembolization (TACE) Plus Sorafenib for the Management of Unresectable Hepatocellular Carcinoma: A Systematic Review of the Literature , 2013, Digestive Diseases and Sciences.
[25] Lihui Weng,et al. An in situ forming biodegradable hydrogel-based embolic agent for interventional therapies. , 2013, Acta biomaterialia.
[26] V. Lam,et al. Transarterial chemoembolization with irinotecan beads in the treatment of colorectal liver metastases: systematic review. , 2013, Journal of vascular and interventional radiology : JVIR.
[27] Lihui Weng,et al. In vitro and in vivo evaluation of biodegradable embolic microspheres with tunable anticancer drug release. , 2013, Acta biomaterialia.
[28] N. Nitta,et al. Evaluation of the embolic effect and degradability of gelatin microspheres and gelpart particles , 2013, Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy.
[29] P. Serruys,et al. Coronary stents: historical development, current status and future directions. , 2013, British medical bulletin.
[30] C. Boni,et al. A phase II randomized dose escalation trial of sorafenib in patients with advanced hepatocellular carcinoma. , 2013, The oncologist.
[31] G. Han,et al. Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: A propensity score matching study , 2013, Journal of digestive diseases.
[32] Raimund Erbel,et al. Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial , 2013, The Lancet.
[33] S. Maithel,et al. Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma. , 2013, Journal of vascular and interventional radiology : JVIR.
[34] J. Jamart,et al. Doxorubicin-loaded drug-eluting beads (DC Bead®) for use in transarterial chemoembolization: A stability assessment , 2013, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
[35] P. Serruys,et al. Five-year follow-up of the ABSORB bioresorbable everolimus-eluting vascular scaffold system: multimodality imaging assessment. , 2013, EuroIntervention.
[36] A. Kastrati,et al. Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials. , 2012, European heart journal.
[37] A. Sood,et al. Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] R. Whitbourn,et al. Clinical and intravascular imaging outcomes at 1 and 2 years after implantation of absorb everolimus eluting bioresorbable vascular scaffolds in small vessels. Late lumen enlargement: does bioresorption matter with small vessel size? Insight from the ABSORB cohort B trial , 2012, Heart.
[39] P. Serruys,et al. TCT-37 Five-year Clinical Outcomes and Non-invasive Angiographic Imaging Results With Functional Assessment After Bioresorbable Everolimus-eluting Scaffold Implantation in Patients with De Novo Coronary Artery Disease , 2012 .
[40] Wan Md Zin Wan Yunus,et al. Mechanical, Thermal and Morphological Properties of Poly(lactic acid)/Epoxidized Palm Olein Blend , 2012, Molecules.
[41] H. Hemker,et al. Thrombin generation: what have we learned? , 2012, Blood reviews.
[42] R. Lencioni. Management of hepatocellular carcinoma with transarterial chemoembolization in the era of systemic targeted therapy. , 2012, Critical reviews in oncology/hematology.
[43] S. Hori,et al. Current status of embolic agents for liver tumor embolization , 2012, International Journal of Clinical Oncology.
[44] G. Dangas,et al. Late Stent Thrombosis: The Last Remaining Obstacle in Coronary Interventional Therapy , 2012, Current Cardiology Reports.
[45] Patrick W Serruys,et al. Everolimus-eluting ABSORB bioresorbable vascular scaffold: present and future perspectives , 2012, Expert review of medical devices.
[46] Patrick W Serruys,et al. The ABSORB bioresorbable vascular scaffold: an evolution or revolution in interventional cardiology? , 2012, Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese.
[47] D. Steinberg,et al. Everolimus-eluting stents in interventional cardiology , 2012, Vascular health and risk management.
[48] W. S. Rasband,et al. ImageJ: Image processing and analysis in Java , 2012 .
[49] J. Bruix,et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. , 2012, Journal of hepatology.
[50] R. Whitbourn,et al. Vascular response of the segments adjacent to the proximal and distal edges of the ABSORB everolimus-eluting bioresorbable vascular scaffold: 6-month and 1-year follow-up assessment: a virtual histology intravascular ultrasound study from the first-in-man ABSORB cohort B trial. , 2012, JACC. Cardiovascular interventions.
[51] P. Serruys,et al. Stent Thrombosis With Everolimus-Eluting Stents: Meta-Analysis of Comparative Randomized Controlled Trials , 2012, Circulation. Cardiovascular interventions.
[52] G. Carrafiello,et al. Quality-Improvement Guidelines for Hepatic Transarterial Chemoembolization , 2012, CardioVascular and Interventional Radiology.
[53] E. Alexopoulou,et al. Chemoembolization With Doxorubicin-Eluting Beads for Unresectable Hepatocellular Carcinoma: Five-Year Survival Analysis , 2012, CardioVascular and Interventional Radiology.
[54] A. Lloyd,et al. Development of a combination drug-eluting bead: towards enhanced efficacy for locoregional tumour therapies , 2012, Anti-cancer drugs.
[55] Patrycja Wojciechowska. The Effect of Concentration and Type of Plasticizer on the Mechanical Properties of Cellulose Acetate Butyrate Organic-Inorganic Hybrids , 2012 .
[56] V. Conteduca,et al. Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial. , 2012, The oncologist.
[57] C. Macaya,et al. Absorbable stent: focus on clinical applications and benefits , 2012, Vascular health and risk management.
[58] Xiabin Jing,et al. Biodegradable synthetic polymers: Preparation, functionalization and biomedical application , 2012 .
[59] David L. Woods,et al. Radiopaque drug-eluting beads for transcatheter embolotherapy: experimental study of drug penetration and coverage in swine. , 2012, Journal of vascular and interventional radiology : JVIR.
[60] Lin Xiao,et al. Poly(Lactic Acid)-Based Biomaterials: Synthesis, Modification and Applications , 2012 .
[61] I. Heschel,et al. Vascular potency of Sus scrofa bone marrow-derived mesenchymal stem cells: a progenitor source of medial but not endothelial cells. , 2012, Tissue engineering. Part A.
[62] R. Maciel Filho,et al. Poly (Lactic Acid) Production for Tissue Engineering Applications , 2012 .
[63] Patrick W Serruys,et al. Four-year clinical follow-up of the ABSORB everolimus-eluting bioresorbable vascular scaffold in patients with de novo coronary artery disease: the ABSORB trial. , 2012, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[64] Rubens Maciel Filho,et al. Poly-lactic acid synthesis for application in biomedical devices - a review. , 2012, Biotechnology advances.
[65] Robert C. G. Martin,et al. Safety and efficacy of trans arterial chemoembolization with drug-eluting beads in hepatocellular cancer: a systematic review. , 2012, Hepato-gastroenterology.
[66] Jian-hua Wang,et al. The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma , 2012, BMC Cancer.
[67] R. Whitbourn,et al. Serial in vivo intravascular ultrasound-based echogenicity changes of everolimus-eluting bioresorbable vascular scaffold during the first 12 months after implantation insights from the ABSORB B trial. , 2011, JACC. Cardiovascular interventions.
[68] C. Bartolozzi,et al. Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma. , 2011, Journal of vascular and interventional radiology : JVIR.
[69] T. Pawlik,et al. Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[70] M. Kudo,et al. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. , 2011, European journal of cancer.
[71] Antonio Colombo,et al. Comparison of coronary bypass surgery with drug-eluting stenting for the treatment of left main and/or three-vessel disease: 3-year follow-up of the SYNTAX trial. , 2011, European heart journal.
[72] Anders Axelsson,et al. The mechanisms of drug release in poly(lactic-co-glycolic acid)-based drug delivery systems--a review. , 2011, International journal of pharmaceutics.
[73] Hongzhi Liu,et al. Research progress in toughening modification of poly(lactic acid) , 2011 .
[74] R. Sauro,et al. Bare-Metal Stents Versus Drug-Eluting Stents for Primary Angioplasty: Long-Term Outcome , 2011, Current cardiology reports.
[75] M. Welker,et al. Anti-angiogenesis in hepatocellular carcinoma treatment: current evidence and future perspectives. , 2011, World journal of gastroenterology.
[76] T. George,et al. The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma , 2011, Alimentary pharmacology & therapeutics.
[77] Cato T Laurencin,et al. Biomedical Applications of Biodegradable Polymers. , 2011, Journal of polymer science. Part B, Polymer physics.
[78] P. Serruys,et al. Bioresorbable scaffold technologies. , 2011, Circulation journal : official journal of the Japanese Circulation Society.
[79] Marisa Masumi Beppu,et al. Natural-based plasticizers and biopolymer films: A review , 2011 .
[80] P. Serruys,et al. Developments in coronary artery stenting: primum non nocere. , 2011, Panminerva medica.
[81] David M Martin,et al. Drug-eluting stents for coronary artery disease: a review. , 2011, Medical engineering & physics.
[82] Dietrich Büsselberg,et al. Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side Effects , 2011, Cancers.
[83] F. H. van der Veen,et al. Hydrophilic surface coatings with embedded biocidal silver nanoparticles and sodium heparin for central venous catheters. , 2011, Biomaterials.
[84] Syam P Nukavarapu,et al. Short-term and long-term effects of orthopedic biodegradable implants. , 2011, Journal of long-term effects of medical implants.
[85] Q. Wei,et al. Improving the blood compatibility of material surfaces via biomolecule-immobilized mussel-inspired coatings. , 2011, Journal of biomedical materials research. Part A.
[86] Y. Dundar,et al. Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes. , 2015, The Cochrane database of systematic reviews.
[87] J. Geschwind,et al. Transcatheter Arterial Chemoembolization for Liver Cancer: Is It Time to Distinguish Conventional from Drug-Eluting Chemoembolization? , 2011, CardioVascular and Interventional Radiology.
[88] J. Benoit,et al. Local implantation of doxorubicin drug eluting beads in rat glioma. , 2010, International journal of pharmaceutics.
[89] C. Mathers,et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.
[90] R. P. John,et al. An overview of the recent developments in polylactide (PLA) research. , 2010, Bioresource technology.
[91] M. Shaver,et al. Tacticity control in the synthesis of poly(lactic acid) polymer stars with dipentaerythritol cores. , 2010, Biomacromolecules.
[92] P. Serruys,et al. Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB trial. , 2010, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[93] Patrick W Serruys,et al. Coronary stents: looking forward. , 2010, Journal of the American College of Cardiology.
[94] P. Serruys,et al. Coronary stents: current status. , 2010, Journal of the American College of Cardiology.
[95] Steve Davies,et al. ORIGINAL RESEARCH: The eco-profile for current Ingeo® polylactide production , 2010 .
[96] David L. Woods,et al. Development of "imageable" beads for transcatheter embolotherapy. , 2010, Journal of vascular and interventional radiology : JVIR.
[97] R. Dhanasekaran,et al. Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC) , 2010, Journal of surgical oncology.
[98] H. Bøtker,et al. Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial , 2010, The Lancet.
[99] I. Krämer,et al. Stability of irinotecan-loaded drug eluting beads (DC BeadTM) used for transarterial chemoembolization , 2010, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
[100] Loes M. J. Kroon-Batenburg,et al. EVAL15: a diffraction data integration method based on ab initio predicted profiles , 2010 .
[101] U. Fiedler,et al. The Potency of Refined Mouse Models: Implications for Clinical Trials , 2010 .
[102] S. Rigby,et al. The initial release of cisplatin from poly(lactide-co-glycolide) microspheres. , 2010, International journal of pharmaceutics.
[103] D. Harnois,et al. Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease Progression , 2010 .
[104] M. Gandolfi,et al. Evaluation of the radiopacity of calcium silicate cements containing different radiopacifiers. , 2010, International endodontic journal.
[105] Anastasia Pomoni,et al. Prospective Randomized Comparison of Chemoembolization with Doxorubicin-Eluting Beads and Bland Embolization with BeadBlock for Hepatocellular Carcinoma , 2010, CardioVascular and Interventional Radiology.
[106] V. Çakır,et al. Looking for the Ideal Particle: An Experimental Embolization Study , 2010, CardioVascular and Interventional Radiology.
[107] R. Rapoza,et al. Design principles and performance of bioresorbable polymeric vascular scaffolds. , 2009, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[108] N. Nitta,et al. Prolonged local persistence of cisplatin-loaded gelatin microspheres and their chemoembolic anti-cancer effect in rabbits. , 2009, European journal of radiology.
[109] T. Vogl,et al. Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V Study , 2009, CardioVascular and Interventional Radiology.
[110] Y. Levy,et al. Evaluation of drug-eluting stents' coating durability--clinical and regulatory implications. , 2009, Journal of biomedical materials research. Part B, Applied biomaterials.
[111] Sung W. Shin. The Current Practice of Transarterial Chemoembolization for the Treatment of Hepatocellular Carcinoma , 2009, Korean journal of radiology.
[112] B. Ashrafi,et al. The influence of a compatibilizer on the thermal and dynamic mechanical properties of PEEK/carbon nanotube composites , 2009, Nanotechnology.
[113] Peter Jüni,et al. Correlation of Intravascular Ultrasound Findings With Histopathological Analysis of Thrombus Aspirates in Patients With Very Late Drug-Eluting Stent Thrombosis , 2009, Circulation.
[114] Richard C. Thompson,et al. Our plastic age , 2009, Philosophical Transactions of the Royal Society B: Biological Sciences.
[115] R. Virmani,et al. Comparison of Inflammatory Response After Implantation of Sirolimus- and Paclitaxel-Eluting Stents in Porcine Coronary Arteries , 2009, Circulation.
[116] A. Lewis. DC Bead™: a major development in the toolbox for the interventional oncologist , 2009, Expert review of medical devices.
[117] C. Isella,et al. The Thioxotriazole Copper(II) Complex A0 Induces Endoplasmic Reticulum Stress and Paraptotic Death in Human Cancer Cells* , 2009, The Journal of Biological Chemistry.
[118] Bochu Wang,et al. Biodegradation of Silk Biomaterials , 2009, International journal of molecular sciences.
[119] Patrick W Serruys,et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods , 2009, The Lancet.
[120] Anthony L. Spek,et al. Structure validation in chemical crystallography , 2009, Acta crystallographica. Section D, Biological crystallography.
[121] P. Serruys,et al. Advances in stent drug delivery: the future is in bioabsorbable stents. , 2009, Expert Opinion on Drug Delivery.
[122] S. Paggi,et al. Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .
[123] P. Sasieni,et al. Cancer mortality in the United Kingdom: projections to the year 2025 , 2008, British Journal of Cancer.
[124] M. Mulcahy,et al. Comparison of hypoxia-inducible factor-1alpha expression before and after transcatheter arterial embolization in rabbit VX2 liver tumors. , 2008, Journal of vascular and interventional radiology : JVIR.
[125] Xiaoping Guo. Radiopaque, barium sulfate‐filled biomedical compounds of a poly(ether‐block‐amide) copolymer , 2008 .
[126] S. Vaidya,et al. An Overview of Embolic Agents , 2008, Seminars in interventional radiology.
[127] L. Lim,et al. Processing technologies for poly(lactic acid) , 2008 .
[128] Renu Virmani,et al. Pathophysiology of vascular healing and stent mediated arterial injury. , 2008, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[129] Mitchell W Krucoff,et al. Postmarket evaluation of breakthrough technologies. , 2008, American heart journal.
[130] R. Virmani,et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. , 2008, Journal of the American College of Cardiology.
[131] J. W. Hirshfeld. Essentials of Restenosis for the Interventional Cardiologist , 2008 .
[132] Bin Wang,et al. Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization , 2008, Acta radiologica.
[133] C. Mario,et al. Biodegradable drug-eluting stents: promises and pitfalls , 2008, The Lancet.
[134] Patrick W Serruys,et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial , 2008, The Lancet.
[135] Alain Bourmaud,et al. Effect of thermo-mechanical cycles on the physico-chemical properties of poly(lactic acid) , 2008 .
[136] Rob W. W. Hooft,et al. Determination of absolute structure using Bayesian statistics on Bijvoet differences , 2008, Journal of applied crystallography.
[137] P. Deluca,et al. A model-dependent approach to correlate accelerated with real-time release from biodegradable microspheres , 2005, AAPS PharmSciTech.
[138] G. Biondi-Zoccai,et al. Safety of drug-coated stents. , 2008, Expert opinion on drug safety.
[139] G. Sheldrick. A short history of SHELX. , 2008, Acta crystallographica. Section A, Foundations of crystallography.
[140] M. Huneault,et al. Effect of nucleation and plasticization on the crystallization of poly(lactic acid) , 2007 .
[141] Y. Inoue,et al. Polymorphous Crystallization and Multiple Melting Behavior of Poly(l-lactide): Molecular Weight Dependence , 2007 .
[142] Michael Joner,et al. Vascular Responses to Drug Eluting Stents: Importance of Delayed Healing , 2007, Arteriosclerosis, thrombosis, and vascular biology.
[143] Raimund Erbel,et al. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial , 2007, The Lancet.
[144] R. Virmani,et al. Pathological Correlates of Late Drug-Eluting Stent Thrombosis: Strut Coverage as a Marker of Endothelialization , 2007, Circulation.
[145] T. Paunesku,et al. Effect of transcatheter arterial embolization on levels of hypoxia-inducible factor-1alpha in rabbit VX2 liver tumors. , 2007, Journal of vascular and interventional radiology : JVIR.
[146] L. Koole,et al. New acrylic microspheres for arterial embolization: combining radiopacity for precise localization with immobilized thrombin to trigger local blood coagulation. , 2007, Biomaterials.
[147] Jeffrey W. Clark,et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. , 2007, The oncologist.
[148] P. Serruys,et al. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. , 2007, The New England journal of medicine.
[149] R. Reis,et al. Water absorption and degradation characteristics of chitosan-based polyesters and hydroxyapatite composites. , 2007, Macromolecular bioscience.
[150] J. Caridi,et al. Renal artery embolization: application and success in patients with renal cell carcinoma and angiomyolipoma. , 2007, Seminars in interventional radiology.
[151] L. Koole,et al. Thrombus formation at the surface of guide-wire models: effects of heparin-releasing or heparin-exposing surface coatings. , 2007, Journal of vascular and interventional radiology : JVIR.
[152] J. Bruix,et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. , 2007, Journal of hepatology.
[153] Michael Joner,et al. Drug-Eluting Stent and Coronary Thrombosis: Biological Mechanisms and Clinical Implications , 2007, Circulation.
[154] D. Gokhale,et al. Lactic acid production from waste sugarcane bagasse derived cellulose , 2007 .
[155] A. Lewis,et al. Irinotecan drug eluting beads for use in chemoembolization: in vitro and in vivo evaluation of drug release properties. , 2007, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[156] S. Wilhelm,et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models , 2007, Cancer Chemotherapy and Pharmacology.
[157] E. Cholongitas,et al. Transarterial Therapy for Hepatocellular Carcinoma: Which Technique Is More Effective? A Systematic Review of Cohort and Randomized Studies , 2007, CardioVascular and Interventional Radiology.
[158] S. Wilhelm,et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. , 2006, Cancer research.
[159] Xiaobo Liu,et al. Kinetics of thermo-oxidative and thermal degradation of poly(d,l-lactide) (PDLLA) at processing temperature , 2006 .
[160] Laura Marelli,et al. Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies. , 2006, Cancer treatment reviews.
[161] S. Wilhelm,et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer , 2006, Nature Reviews Drug Discovery.
[162] Tzong‐Ming Wu,et al. Biodegradable poly(lactic acid)/chitosan-modified montmorillonite nanocomposites: Preparation and characterization , 2006 .
[163] A. Lewis,et al. Pharmacokinetic and safety study of doxorubicin-eluting beads in a porcine model of hepatic arterial embolization. , 2006, Journal of vascular and interventional radiology : JVIR.
[164] Hyun Jung Chung,et al. Heparin Immobilized Porous PLGA Microspheres for Angiogenic Growth Factor Delivery , 2006, Pharmaceutical Research.
[165] Sanjay Deshmukh,et al. Studies Toward Producing Eco-Friendly Plastics , 2006 .
[166] H. Chung,et al. Biodegradable polymeric microspheres with "open/closed" pores for sustained release of human growth hormone. , 2006, Journal of controlled release : official journal of the Controlled Release Society.
[167] P. Simamora,et al. Poly-L-lactic acid: an overview. , 2006, Journal of drugs in dermatology : JDD.
[168] A. Lloyd,et al. DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. , 2006, Journal of vascular and interventional radiology : JVIR.
[169] H. Hemker,et al. Thrombin generation, a function test of the haemostaticthrombotic system , 2006, Thrombosis and Haemostasis.
[170] R. Virmani,et al. Differential Response of Delayed Healing and Persistent Inflammation at Sites of Overlapping Sirolimus- or Paclitaxel-Eluting Stents , 2005, Circulation.
[171] Jianbo Ji,et al. Studies on the poly(lactic-co-glycolic) acid microspheres of cisplatin for lung-targeting. , 2005, International journal of pharmaceutics.
[172] Linbo Wu,et al. In vitro degradation of three-dimensional porous poly(D,L-lactide-co-glycolide) scaffolds for tissue engineering. , 2004, Biomaterials.
[173] Kenji Okamura,et al. Tensile properties and biological response of poly(L-lactic acid) felt graft: an experimental trial for rotator-cuff reconstruction. , 2004, Journal of biomedical materials research. Part B, Applied biomaterials.
[174] Douglas E. Hirt,et al. Modification of poly(lactic acid) films: Enhanced wettability from surface-confined photografting and increased degradation rate due to an artifact of the photografting process , 2004 .
[175] D. Auclair,et al. BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.
[176] J. Truebenbach,et al. Radiopacity of current endovascular stents: evaluation in a multiple reader phantom study. , 2004, Journal of vascular and interventional radiology : JVIR.
[177] T. Park,et al. Comparative study on sustained release of human growth hormone from semi-crystalline poly(L-lactic acid) and amorphous poly(D,L-lactic-co-glycolic acid) microspheres: morphological effect on protein release. , 2004, Journal of controlled release : official journal of the Controlled Release Society.
[178] L. Koole,et al. Coils and tubes releasing heparin. Studies on a new vascular graft prototype. , 2004, Biomaterials.
[179] O. Corrigan,et al. Effect of poly-hydroxy aliphatic ester polymer type on amoxycillin release from cylindrical compacts. , 2003, International journal of pharmaceutics.
[180] T. Boulikas,et al. Cisplatin and platinum drugs at the molecular level. (Review). , 2003, Oncology reports.
[181] Z. Siddik,et al. Cisplatin: mode of cytotoxic action and molecular basis of resistance , 2003, Oncogene.
[182] D. Sawyer. Bioprocessing – no longer a field of dreams , 2003 .
[183] J. Perez,et al. Cisplatin biochemical mechanism of action: from cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways. , 2003, Current medicinal chemistry.
[184] David A. Glassner,et al. Applications of life cycle assessment to NatureWorks polylactide (PLA) production , 2003 .
[185] J. Folkman. Role of angiogenesis in tumor growth and metastasis. , 2002, Seminars in oncology.
[186] A. Södergård,et al. Properties of lactic acid based polymers and their correlation with composition , 2002 .
[187] B. Desoize,et al. Particular aspects of platinum compounds used at present in cancer treatment. , 2002, Critical reviews in oncology/hematology.
[188] Nureddin Ashammakhi,et al. Strength retention properties of self-reinforced poly L-lactide (SR-PLLA) sutures compared with polyglyconate (Maxon) and polydioxanone (PDS) sutures. An in vitro study. , 2002, Biomaterials.
[189] Keigo Aoi,et al. Stereoselective ring-opening polymerization of racemic lactide using aluminum-achiral ligand complexes: exploration of a chain-end control mechanism. , 2002, Journal of the American Chemical Society.
[190] S. Hyon,et al. An Experimental Study of Regional Chemotherapy Using CDDP-Loaded Microspheres for Esophageal Cancer , 2002, Surgery Today.
[191] A. Lloyd,et al. Interfacial bioengineering to enhance surface biocompatibility. , 2002, Medical device technology.
[192] P. Moroz,et al. Targeting liver tumors with hyperthermia: Ferromagnetic embolization in a rabbit liver tumor model , 2001, Journal of surgical oncology.
[193] J. Tasto,et al. Bioabsorbable implants in orthopaedics: new developments and clinical applications. , 2001, The Journal of the American Academy of Orthopaedic Surgeons.
[194] L. Avérous,et al. Poly(lactic acid): plasticization and properties of biodegradable multiphase systems , 2001 .
[195] G. Yalcin,et al. THE SPECTROPHOTOMETRIC DETERMINATION OF CISPLATIN IN URINE, USING o-PHENYLENEDIAMINE AS DERIVATIZING AGENT , 2001 .
[196] L. Claes,et al. Resorbable polymer fibers for ligament augmentation. , 2001, Journal of biomedical materials research.
[197] P. Gruber,et al. Polylactic Acid Technology , 2000 .
[198] J. Vacanti,et al. In vitro degradation of porous poly(L-lactic acid) foams. , 2000, Biomaterials.
[199] H. Uehata,et al. Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. , 2000, Circulation.
[200] M. Léonard,et al. Surface modification of poly(lactic acid) nanospheres using hydrophobically modified dextrans as stabilizers in an o/w emulsion/evaporation technique. , 2000, Journal of biomedical materials research.
[201] Y. Machida,et al. Pharmacokinetics of prolonged-release CPT-11-loaded microspheres in rats. , 2000, Journal of controlled release : official journal of the Controlled Release Society.
[202] Gregory L. Baker,et al. Stereoselective polymerization of a racemic monomer with a racemic catalyst: Direct preparation of the polylactic acid stereocomplex from racemic lactide , 2000 .
[203] Y. Ikada,et al. Biodegradable polyesters for medical and ecological applications , 2000 .
[204] D. Rüfenacht,et al. Radiopaque polymeric materials for medical applications. Current aspects of biomaterial research. , 1999, Investigative radiology.
[205] T. Park,et al. A new preparation method for protein loaded poly(D, L-lactic-co-glycolic acid) microspheres and protein release mechanism study. , 1998, Journal of controlled release : official journal of the Controlled Release Society.
[206] M. Al-Ahwal,et al. Chemoembolization in hepatocellular carcinoma. , 1998, Saudi medical journal.
[207] J. Lunt. Large-scale production, properties and commercial applications of polylactic acid polymers , 1998 .
[208] O'donnell,et al. Preparation of microspheres by the solvent evaporation technique. , 1997, Advanced drug delivery reviews.
[209] I. Cabasso,et al. Radiopaque copolymers of styryldiphenylbismuth vinylbenzylphosphonate and methyl methacrylate , 1997 .
[210] Y Ikada,et al. Synthesis of polylactides with different molecular weights. , 1997, Biomaterials.
[211] D. Murray,et al. Radio-opaque agents in bone cement increase bone resorption. , 1997, The Journal of bone and joint surgery. British volume.
[212] Stephen P. McCarthy,et al. Effects of physical aging, crystallinity, and orientation on the enzymatic degradation of poly(lactic acid) , 1996 .
[213] O. Böstman,et al. Absorbable devices in the fixation of fractures. , 1996, The Journal of trauma.
[214] S. Wallace,et al. Percutaneous intratumoral injection of cisplatin microspheres in tumor-bearing rats to diminish acute nephrotoxicity , 1996, Anti-cancer drugs.
[215] Catia Bastioli,et al. Effect of molecular weight and crystallinity on poly(lactic acid) mechanical properties , 1996 .
[216] H. Kricheldorf,et al. Polylactides ‐ synthesis, characterization and medical application , 1996 .
[217] C. M. Agrawal,et al. Sterilization, toxicity, biocompatibility and clinical applications of polylactic acid/polyglycolic acid copolymers. , 1996, Biomaterials.
[218] R. Mehta,et al. Prediction of solvent removal profile and effect on properties for peptide-loaded PLGA microspheres prepared by solvent extraction/ evaporation method , 1995 .
[219] M. Jonkman,et al. Reinforced poly(L-lactic acid) fibres as suture material. , 1995, Journal of applied biomaterials : an official journal of the Society for Biomaterials.
[220] Raymond E. Davis,et al. Patterns in Hydrogen Bonding: Functionality and Graph Set Analysis in Crystals , 1995 .
[221] Kazuhiko Suzuki,et al. Basic Properties of Polylactic Acid Produced by the Direct Condensation Polymerization of Lactic Acid , 1995 .
[222] Suming Li,et al. Hydrolytic degradation of devices based on poly(DL-lactic acid) size-dependence. , 1995, Biomaterials.
[223] Tae Gwan Park,et al. Degradation of poly(d,l-lactic acid) microspheres: effect of molecular weight , 1994 .
[224] Stephen P. McCarthy,et al. Polylactide stereochemistry: effect on enzymic degradability , 1994 .
[225] D. Pichora,et al. An Investigation of Poly(lactic acid) Degradation , 1994 .
[226] G. Dusheiko,et al. Management of hepatocellular carcinoma. , 1992, Journal of hepatology.
[227] M. Scandola,et al. Thermal properties and physical ageing of poly (l-lactic acid) , 1992 .
[228] P. Törmälä,et al. Absorption, biocompatibility, and fixation properties of polylactic acid in bone tissue: an experimental study in rats. , 1991, Clinical orthopaedics and related research.
[229] R. Jalil,et al. Biodegradable poly(lactic acid) and poly(lactide-co-glycolide) microcapsules: problems associated with preparative techniques and release properties. , 1990, Journal of microencapsulation.
[230] J. Benoit,et al. Formation and characterization of cisplatin loaded poly(d,l-lactide) microspheres for chemoembolization. , 1986, Journal of pharmaceutical sciences.
[231] T. Kondo,et al. Mechanism of hydrolytic degradation of poly(L-lactide) microcapsules: effects of pH, ionic strength and buffer concentration. , 1986, Journal of microencapsulation.
[232] D. Woodfield. Hepatocellular carcinoma. , 1986, The New Zealand medical journal.
[233] T. Mosmann. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.
[234] H. Flack,et al. On enantiomorph‐polarity estimation , 1983 .
[235] G L Kimmel,et al. Aliphatic polyesters II. The degradation of poly (DL-lactide), poly (epsilon-caprolactone), and their copolymers in vivo. , 1981, Biomaterials.
[236] A. Schindler,et al. Polylactide. II. Viscosity–molecular weight relationships and unperturbed chain dimensions , 1979 .
[237] R. White,et al. Long term follow-up of transcatheter embolization with autologous clot, oxycel and gelfoam in domestic swine. , 1977, Investigative radiology.
[238] G. Wegner,et al. Investigation of the structure of solution grown crystals of lactide copolymers by means of chemical reactions , 1973 .
[239] G. H. Ayres,et al. Spectrophotometric determination of platinum with o-phenylenediamine. , 1973, Talanta.
[240] F Leonard,et al. Biodegradable poly(lactic acid) polymers. , 1971, Journal of biomedical materials research.
[241] K C Pani,et al. Polylactic acid for surgical implants , 1966, Archives of surgery.